カテゴリ： QYResearch, 世界, 医療/バイオ

原発性卵巣機能不全治療の世界市場2023年：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他

■ 英語タイトル：Global Primary Ovarian Insufficiency Therapy Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA7536）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA7536
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：88
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥435,000見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥652,500見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥870,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[原発性卵巣機能不全治療の世界市場2023年：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は原発性卵巣機能不全治療のグローバル市場について調査・分析し、世界の原発性卵巣機能不全治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他）、用途別セグメント分析（20歳以下、20～30歳、30～45歳、45歳以上）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVFなどが含まれています。原発性卵巣機能不全治療のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、原発性卵巣機能不全治療市場規模を算出する際に考慮しました。

・原発性卵巣機能不全治療市場の概要
- 原発性卵巣機能不全治療の種類別セグメント
- 世界の原発性卵巣機能不全治療市場規模：タイプ別分析（ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他）
- 原発性卵巣機能不全治療の用途別セグメント
- 世界の原発性卵巣機能不全治療市場規模：用途別分析（20歳以下、20～30歳、30～45歳、45歳以上）
- 世界の原発性卵巣機能不全治療市場規模予測（2018年-2029年）

・原発性卵巣機能不全治療市場の成長トレンド
- 原発性卵巣機能不全治療の地域別市場規模（2018年-2029年）
- 原発性卵巣機能不全治療市場ダイナミクス
- 原発性卵巣機能不全治療の業界動向
- 原発性卵巣機能不全治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他
- 世界の原発性卵巣機能不全治療のタイプ別市場規模（2018年-2023年）
- 世界の原発性卵巣機能不全治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：20歳以下、20～30歳、30～45歳、45歳以上
- 世界の原発性卵巣機能不全治療の用途別市場規模（2018年-2023年）
- 世界の原発性卵巣機能不全治療の用途別市場規模（2024年-2029年）

・原発性卵巣機能不全治療の地域別市場規模
- 北米の原発性卵巣機能不全治療市場規模（2018年-2029年）
- 米国の原発性卵巣機能不全治療市場規模（2018年-2029年）
- ヨーロッパの原発性卵巣機能不全治療市場規模（2018年-2029年）
- アジア太平洋の原発性卵巣機能不全治療市場規模（2018年-2029年）
- 中国の原発性卵巣機能不全治療市場規模（2018年-2029年）
- 日本の原発性卵巣機能不全治療市場規模（2018年-2029年）
- 韓国の原発性卵巣機能不全治療市場規模（2018年-2029年）
- インドの原発性卵巣機能不全治療市場規模（2018年-2029年）
- オーストラリアの原発性卵巣機能不全治療市場規模（2018年-2029年）
- 中南米の原発性卵巣機能不全治療市場規模（2018年-2029年）
- 中東・アフリカの原発性卵巣機能不全治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Pfizer、Bayer、Novartis、Bioscience Institute、Johns Hopkins Medicine、Mayo Clinic、Baptist Health、Indira IVF

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Primary Ovarian Insufficiency Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Primary Ovarian Insufficiency Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Primary Ovarian Insufficiency Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Primary Ovarian Insufficiency Therapy in Less than 20 Years Old is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Primary Ovarian Insufficiency Therapy include Pfizer, Bayer, Novartis, Bioscience Institute, Johns Hopkins Medicine, Mayo Clinic, Baptist Health and Indira IVF, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Primary Ovarian Insufficiency Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Primary Ovarian Insufficiency Therapy.
The Primary Ovarian Insufficiency Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Primary Ovarian Insufficiency Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Primary Ovarian Insufficiency Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Bayer
Novartis
Bioscience Institute
Johns Hopkins Medicine
Mayo Clinic
Baptist Health
Indira IVF
Segment by Type
Hormone Replacement Therapy (HRT)
Calcium and Vitamin D Supplements
In Vitro Fertilization (IVF)
Stem Cell Therapy
Others
Segment by Application
Less than 20 Years Old
20 to 30 Years Old
30 to 45 Years Old
45 Years Old and Older
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Primary Ovarian Insufficiency Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Hormone Replacement Therapy (HRT)
1.2.3 Calcium and Vitamin D Supplements
1.2.4 In Vitro Fertilization (IVF)
1.2.5 Stem Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Primary Ovarian Insufficiency Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Less than 20 Years Old
1.3.3 20 to 30 Years Old
1.3.4 30 to 45 Years Old
1.3.5 45 Years Old and Older
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Ovarian Insufficiency Therapy Market Perspective (2018-2029)
2.2 Primary Ovarian Insufficiency Therapy Growth Trends by Region
2.2.1 Global Primary Ovarian Insufficiency Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Ovarian Insufficiency Therapy Historic Market Size by Region (2018-2023)
2.2.3 Primary Ovarian Insufficiency Therapy Forecasted Market Size by Region (2024-2029)
2.3 Primary Ovarian Insufficiency Therapy Market Dynamics
2.3.1 Primary Ovarian Insufficiency Therapy Industry Trends
2.3.2 Primary Ovarian Insufficiency Therapy Market Drivers
2.3.3 Primary Ovarian Insufficiency Therapy Market Challenges
2.3.4 Primary Ovarian Insufficiency Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue
3.1.1 Global Top Primary Ovarian Insufficiency Therapy Players by Revenue (2018-2023)
3.1.2 Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Primary Ovarian Insufficiency Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Ovarian Insufficiency Therapy Revenue
3.4 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio
3.4.1 Global Primary Ovarian Insufficiency Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Ovarian Insufficiency Therapy Revenue in 2022
3.5 Primary Ovarian Insufficiency Therapy Key Players Head office and Area Served
3.6 Key Players Primary Ovarian Insufficiency Therapy Product Solution and Service
3.7 Date of Enter into Primary Ovarian Insufficiency Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Ovarian Insufficiency Therapy Breakdown Data by Type
4.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Type (2018-2023)
4.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Type (2024-2029)
5 Primary Ovarian Insufficiency Therapy Breakdown Data by Application
5.1 Global Primary Ovarian Insufficiency Therapy Historic Market Size by Application (2018-2023)
5.2 Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
6.2 North America Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
6.4 North America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
7.2 Europe Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
7.4 Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
8.2 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
9.2 Latin America Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
9.4 Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size (2018-2029)
10.2 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Primary Ovarian Insufficiency Therapy Introduction
11.1.4 Pfizer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Bayer
11.2.1 Bayer Company Detail
11.2.2 Bayer Business Overview
11.2.3 Bayer Primary Ovarian Insufficiency Therapy Introduction
11.2.4 Bayer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.2.5 Bayer Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Primary Ovarian Insufficiency Therapy Introduction
11.3.4 Novartis Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Bioscience Institute
11.4.1 Bioscience Institute Company Detail
11.4.2 Bioscience Institute Business Overview
11.4.3 Bioscience Institute Primary Ovarian Insufficiency Therapy Introduction
11.4.4 Bioscience Institute Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.4.5 Bioscience Institute Recent Development
11.5 Johns Hopkins Medicine
11.5.1 Johns Hopkins Medicine Company Detail
11.5.2 Johns Hopkins Medicine Business Overview
11.5.3 Johns Hopkins Medicine Primary Ovarian Insufficiency Therapy Introduction
11.5.4 Johns Hopkins Medicine Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.5.5 Johns Hopkins Medicine Recent Development
11.6 Mayo Clinic
11.6.1 Mayo Clinic Company Detail
11.6.2 Mayo Clinic Business Overview
11.6.3 Mayo Clinic Primary Ovarian Insufficiency Therapy Introduction
11.6.4 Mayo Clinic Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.6.5 Mayo Clinic Recent Development
11.7 Baptist Health
11.7.1 Baptist Health Company Detail
11.7.2 Baptist Health Business Overview
11.7.3 Baptist Health Primary Ovarian Insufficiency Therapy Introduction
11.7.4 Baptist Health Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.7.5 Baptist Health Recent Development
11.8 Indira IVF
11.8.1 Indira IVF Company Detail
11.8.2 Indira IVF Business Overview
11.8.3 Indira IVF Primary Ovarian Insufficiency Therapy Introduction
11.8.4 Indira IVF Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023)
11.8.5 Indira IVF Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Hormone Replacement Therapy (HRT)
Table 3. Key Players of Calcium and Vitamin D Supplements
Table 4. Key Players of In Vitro Fertilization (IVF)
Table 5. Key Players of Stem Cell Therapy
Table 6. Key Players of Others
Table 7. Global Primary Ovarian Insufficiency Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Primary Ovarian Insufficiency Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Primary Ovarian Insufficiency Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Primary Ovarian Insufficiency Therapy Market Share by Region (2018-2023)
Table 11. Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Primary Ovarian Insufficiency Therapy Market Share by Region (2024-2029)
Table 13. Primary Ovarian Insufficiency Therapy Market Trends
Table 14. Primary Ovarian Insufficiency Therapy Market Drivers
Table 15. Primary Ovarian Insufficiency Therapy Market Challenges
Table 16. Primary Ovarian Insufficiency Therapy Market Restraints
Table 17. Global Primary Ovarian Insufficiency Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Primary Ovarian Insufficiency Therapy Market Share by Players (2018-2023)
Table 19. Global Top Primary Ovarian Insufficiency Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Ovarian Insufficiency Therapy as of 2022)
Table 20. Ranking of Global Top Primary Ovarian Insufficiency Therapy Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Primary Ovarian Insufficiency Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Primary Ovarian Insufficiency Therapy Product Solution and Service
Table 24. Date of Enter into Primary Ovarian Insufficiency Therapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Ovarian Insufficiency Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Type (2018-2023)
Table 28. Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Type (2024-2029)
Table 30. Global Primary Ovarian Insufficiency Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Application (2018-2023)
Table 32. Global Primary Ovarian Insufficiency Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Primary Ovarian Insufficiency Therapy Revenue Market Share by Application (2024-2029)
Table 34. North America Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 49. Pfizer Company Detail
Table 50. Pfizer Business Overview
Table 51. Pfizer Primary Ovarian Insufficiency Therapy Product
Table 52. Pfizer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 53. Pfizer Recent Development
Table 54. Bayer Company Detail
Table 55. Bayer Business Overview
Table 56. Bayer Primary Ovarian Insufficiency Therapy Product
Table 57. Bayer Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 58. Bayer Recent Development
Table 59. Novartis Company Detail
Table 60. Novartis Business Overview
Table 61. Novartis Primary Ovarian Insufficiency Therapy Product
Table 62. Novartis Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 63. Novartis Recent Development
Table 64. Bioscience Institute Company Detail
Table 65. Bioscience Institute Business Overview
Table 66. Bioscience Institute Primary Ovarian Insufficiency Therapy Product
Table 67. Bioscience Institute Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 68. Bioscience Institute Recent Development
Table 69. Johns Hopkins Medicine Company Detail
Table 70. Johns Hopkins Medicine Business Overview
Table 71. Johns Hopkins Medicine Primary Ovarian Insufficiency Therapy Product
Table 72. Johns Hopkins Medicine Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 73. Johns Hopkins Medicine Recent Development
Table 74. Mayo Clinic Company Detail
Table 75. Mayo Clinic Business Overview
Table 76. Mayo Clinic Primary Ovarian Insufficiency Therapy Product
Table 77. Mayo Clinic Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 78. Mayo Clinic Recent Development
Table 79. Baptist Health Company Detail
Table 80. Baptist Health Business Overview
Table 81. Baptist Health Primary Ovarian Insufficiency Therapy Product
Table 82. Baptist Health Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 83. Baptist Health Recent Development
Table 84. Indira IVF Company Detail
Table 85. Indira IVF Business Overview
Table 86. Indira IVF Primary Ovarian Insufficiency Therapy Product
Table 87. Indira IVF Revenue in Primary Ovarian Insufficiency Therapy Business (2018-2023) & (US$ Million)
Table 88. Indira IVF Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Ovarian Insufficiency Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Primary Ovarian Insufficiency Therapy Market Share by Type: 2022 VS 2029
Figure 3. Hormone Replacement Therapy (HRT) Features
Figure 4. Calcium and Vitamin D Supplements Features
Figure 5. In Vitro Fertilization (IVF) Features
Figure 6. Stem Cell Therapy Features
Figure 7. Others Features
Figure 8. Global Primary Ovarian Insufficiency Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Primary Ovarian Insufficiency Therapy Market Share by Application: 2022 VS 2029
Figure 10. Less than 20 Years Old Case Studies
Figure 11. 20 to 30 Years Old Case Studies
Figure 12. 30 to 45 Years Old Case Studies
Figure 13. 45 Years Old and Older Case Studies
Figure 14. Primary Ovarian Insufficiency Therapy Report Years Considered
Figure 15. Global Primary Ovarian Insufficiency Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Primary Ovarian Insufficiency Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Primary Ovarian Insufficiency Therapy Market Share by Region: 2022 VS 2029
Figure 18. Global Primary Ovarian Insufficiency Therapy Market Share by Players in 2022
Figure 19. Global Top Primary Ovarian Insufficiency Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Ovarian Insufficiency Therapy as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Primary Ovarian Insufficiency Therapy Revenue in 2022
Figure 21. North America Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Primary Ovarian Insufficiency Therapy Market Share by Country (2018-2029)
Figure 23. United States Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Primary Ovarian Insufficiency Therapy Market Share by Country (2018-2029)
Figure 27. Germany Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Primary Ovarian Insufficiency Therapy Market Share by Region (2018-2029)
Figure 35. China Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Primary Ovarian Insufficiency Therapy Market Share by Country (2018-2029)
Figure 43. Mexico Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Primary Ovarian Insufficiency Therapy Market Share by Country (2018-2029)
Figure 47. Turkey Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Primary Ovarian Insufficiency Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Pfizer Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 50. Bayer Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 51. Novartis Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 52. Bioscience Institute Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 53. Johns Hopkins Medicine Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 54. Mayo Clinic Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 55. Baptist Health Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 56. Indira IVF Revenue Growth Rate in Primary Ovarian Insufficiency Therapy Business (2018-2023)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • パジェット病治療のグローバル市場（2022年-2029年）：ビスフォスフォネート、カルシトニン類似体（サケカルシトニン）、鎮痛薬、カルシウム、ビタミンDサプリメント
  • β-ヒドロキシ-β-メチル酪酸カルシウム（HMB-Ca）APIのグローバル市場2023：カルシウム （g/100g）: 13-13.9%、 カルシウム （g/100g）: 14-14.9%、 カルシウム （g/100g）: 15-15.9%、 カルシウム （g/100g）: 16%、 その他
  • ホルモン補充療法（HRT）のグローバル市場：産業動向、シェア、規模、成長、機会・予測（2022～2028）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA7536 )"原発性卵巣機能不全治療の世界市場2023年：ホルモン補充療法（HRT）、カルシウム/ビタミンDサプリメント、体外受精（IVF）、幹細胞療法、その他" (英文：Global Primary Ovarian Insufficiency Therapy Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。